{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T03:19:01Z","timestamp":1787282341680,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jval.2018.06.011","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T19:37:30Z","timestamp":1533325050000},"page":"1062-1068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing"],"prefix":"10.1016","volume":"21","author":[{"given":"Julia R.","family":"Trosman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Al B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Balch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2018.06.011_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2018.06.011_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3410\/B1-73","article-title":"Customized care 2020: how medical sequencing and network biology will enable personalized medicine","volume":"1","author":"Boguski","year":"2009","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.jval.2018.06.011_bib3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1200\/JCO.2012.45.2268","article-title":"Genomic medicine frontier in human solid tumors: prospects and challenges","volume":"31","author":"Dienstmann","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2018.06.011_bib4","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1377\/hlthaff.2014.0020","article-title":"Genomic sequencing: assessing the health care system, policy, and big-data implications","volume":"33","author":"Phillips","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2018.06.011_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jlme.12160","article-title":"Clinical integration of next generation sequencing: coverage and reimbursement challenges","volume":"42","author":"Deverka","year":"2014","journal-title":"J Law Med Ethics"},{"key":"10.1016\/j.jval.2018.06.011_bib6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.2014.14915","article-title":"Overcoming the reimbursement barriers for clinical sequencing","volume":"312","author":"Deverka","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.06.011_bib7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nbt.3322","article-title":"Availability and payer coverage of BRCA1\/2 tests and gene panels","volume":"33","author":"Clain","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jval.2018.06.011_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv030","article-title":"Marketing of personalized cancer care on the web: an analysis of Internet websites","volume":"107","author":"Gray","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2018.06.011_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/gim.2012.157","article-title":"Implementing genomic medicine in the clinic: the future is here","volume":"15","author":"Manolio","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.jval.2018.06.011_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.atherosclerosis.2016.08.034","article-title":"Implementing genomics and pharmacogenomics in the clinic: the National Human Genome Research Institute\u2019s genomic medicine portfolio","volume":"253","author":"Manolio","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jval.2018.06.011_bib11","series-title":"The Economics of Genomic Medicine: Workshop Summary","author":"Berger","year":"2013"},{"key":"10.1016\/j.jval.2018.06.011_bib12","first-page":"9","article-title":"Association of insurance with cancer care utilization and outcomes","volume":"58","author":"Ward","year":"2008","journal-title":"CA Cancer J Clin"},{"issue":"Suppl. 6","key":"10.1016\/j.jval.2018.06.011_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0138","article-title":"NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement","volume":"9","author":"Engstrom","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2018.06.011_bib14","series-title":"Integrating Large-Scale Genomic Information into Clinical Practice: Workshop Summary","author":"Olson","year":"2012"},{"key":"10.1016\/j.jval.2018.06.011_bib15","doi-asserted-by":"crossref","unstructured":"Laurene A. Graig, Jonathan K. Phillips, and Harold L. Moses, Editors. Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine. Washington, DC: The National Academies Press, 2016","DOI":"10.17226\/21860"},{"key":"10.1016\/j.jval.2018.06.011_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.6004\/jnccn.2015.0043","article-title":"Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh","volume":"13","author":"Trosman","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2018.06.011_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.6004\/jnccn.2017.0022","article-title":"Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the precision medicine initiative","volume":"15","author":"Trosman","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2018.06.011_bib18","unstructured":"Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, Rapporteurs. Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary. Washington, DC: The National Academies Press, 2015"},{"key":"10.1016\/j.jval.2018.06.011_bib19","year":"2015","journal-title":"Initial medical policy and model coverage guidelines for clinical next generation sequencing in oncology. Report and recommendations"},{"key":"10.1016\/j.jval.2018.06.011_bib20","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jval.2018.06.011_bib21","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jval.2018.06.011_bib22","unstructured":"Center for Medicare & Medicaid Services. Decision memo for next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer (CAG-00450N). Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=290&bc=AAAAAAAAACAA. [Accessed May 3, 2018]."},{"key":"10.1016\/j.jval.2018.06.011_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdx786","article-title":"Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it","volume":"29","author":"Prasad","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2018.06.011_bib24","author":"Quinn","year":"2018","journal-title":"Medicare\u2019s universal NCD for next generation sequencing in cancer patients: understanding its scope and implications"},{"key":"10.1016\/j.jval.2018.06.011_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1126\/science.aas9268","article-title":"Insurance coverage for genomic tests","volume":"360","author":"Phillips","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jval.2018.06.011_bib26","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1001\/jama.2018.4863","article-title":"Evolving payer coverage policies on genomic sequencing tests: Beginning of the end or end of the beginning?","volume":"319","author":"Phillips","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2018.06.011_bib27","unstructured":"Center for Medicare & Medicaid Services. View public comments for next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-view-public-comments.aspx?NCAId=290&ExpandComments=n&bc=ACAAAAAACAAAAA%3D%3D&. [Accessed March 11, 2018]."},{"issue":"Suppl. 4","key":"10.1016\/j.jval.2018.06.011_bib28","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.6004\/jnccn.2013.0221","article-title":"Multigene assays in metastatic colorectal cancer","volume":"11","author":"Deeb","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jval.2018.06.011_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmoldx.2012.04.006","article-title":"Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the Association for Molecular Pathology","volume":"14","author":"Schrijver","year":"2012","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jval.2018.06.011_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060116-022926","article-title":"Molecular and genomic determinants of response to immune checkpoint inhibition in cancer","volume":"69","author":"Jenkins","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jval.2018.06.011_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.clpt.6100319","article-title":"Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges","volume":"82","author":"Deverka","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jval.2018.06.011_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JOP.000075","article-title":"Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay","volume":"6","author":"Trosman","year":"2010","journal-title":"J Oncol Pract"},{"issue":"Suppl. 5","key":"10.1016\/j.jval.2018.06.011_bib33","first-page":"SP53","article-title":"Health technology assessment and private payers\u2019 coverage of personalized medicine","volume":"17","author":"Trosman","year":"2011","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jval.2018.06.011_bib34","series-title":"Perspectives on Essential Health Benefits: Workshop Report","year":"2012"},{"key":"10.1016\/j.jval.2018.06.011_bib35","unstructured":"National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#site. [Accessed November 7, 2017]."},{"key":"10.1016\/j.jval.2018.06.011_bib36","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2014.57.1422","article-title":"Responsibility for costs associated with clinical trials","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2018.06.011_bib37","unstructured":"Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm560040.htm. [Accessed November 1, 2017]."},{"key":"10.1016\/j.jval.2018.06.011_bib38","unstructured":"National Academies of Sciences, Engineering, and Medicine. 2017. An evidence framework for genetic testing. Washington, DC: The National Academies Press. 10.17226\/24632"},{"key":"10.1016\/j.jval.2018.06.011_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2013-0392","article-title":"A new model for reimbursing genome-based cancer care","volume":"19","author":"Ramsey","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2018.06.011_bib40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nbt.3912","article-title":"Payer coverage policies for multigene tests","volume":"35","author":"Phillips","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jval.2018.06.011_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements\u2014good practices for design, implementation, and evaluation: report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2018.06.011_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13167-017-0078-6","article-title":"Innovative payer engagement strategies: Will the convergence lead to better value creation in personalized medicine?","volume":"8","author":"Akhmetov","year":"2017","journal-title":"EPMA J"},{"key":"10.1016\/j.jval.2018.06.011_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","article-title":"Performance-based risk-sharing arrangements: an updated international review","volume":"35","author":"Carlson","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.06.011_bib44","unstructured":"Palmetto GBA. Molecular Diagnostic Program (MolDX\u00ae). Coverage, coding, and pricing standards and requirements (M00106). 2017. Available from: https:\/\/palmettogba.com\/Palmetto\/moldx.Nsf\/files\/MolDX_Manual.pdf\/$File\/MolDX_Manual.pdf. [Accessed November 4, 2017]."},{"key":"10.1016\/j.jval.2018.06.011_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11530850-000000000-00000","article-title":"Access with evidence development schemes: a framework for description and evaluation","volume":"28","author":"McCabe","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2018.06.011_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jval.2015.10.006","article-title":"New French coverage with evidence development for innovative medical devices: improvements and unresolved issues","volume":"19","author":"Martelli","year":"2016","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518322605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301518322605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:12:47Z","timestamp":1761095567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301518322605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1098301518322605"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2018.06.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2018.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}